机译:Five years after PACIFIC: update on multimodal treatment efficacy based on real-world reports
University of Munich,Ludwig Maximilians Univ Munchen;
Immunoanalyt Tissue Control Immunocytes,Helmholtz Zentrum Munchen;
Checkpoint inhibition; durvalumab; interferon gamma; PD-L1; mutational landscape; non-small cell lung cancer; tumor-infiltrating lymphocytes; tumor microenvironment; CELL LUNG-CANCER; LOCAL-REGIONAL CONTROL; OPEN-LABEL; CONCURRENT CHEMORADIOTHERAPY; PREDICTIVE BIOMARKERS; ADJUVANT DURVALUMAB; PD-L1 EXPRESSION; NSCLC; CHEMORADIATION; IMMUNOTHERAPY;